Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab +/- OSI-906 in Platinum-Refractory HNSCC
NCT01427205Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of linsitinib in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 24 months. Planned start Jun 2013; status: withdrawn.
02
Drugs
linsitinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01427205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427205.